Human disease
chronic myeloid leukemia
Mondo defines it as: “A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.”
2 disease groups in OMIA reach this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1513 | Leukaemia, chronic myelogenous | OMIA's OMIM numbers | 2 | Drug |
85.8
|
| 1573 | Leukaemia, chronic monocytic | OMIA's OMIM numbers | 1 | Drug |
82.8
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| ABL1 | 0.82 | 7,216 |
| BCR | 0.82 | 8,089 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Asciminib | ABL1, BCR | Approved |
| Bosutinib | ABL1, BCR | Approved |
| Busulfan | None of these genes | Approved |
| Dasatinib Anhydrous | ABL1, BCR | Approved |
| Hydroxyurea | None of these genes | Approved |
| Imatinib | ABL1, BCR | Approved |
| Interferon Alfa-2b | None of these genes | Approved |
| Nilotinib | ABL1, BCR | Approved |
| Ponatinib | ABL1, BCR | Approved |
| Antilymphocyte Immunoglobulin (Horse) | None of these genes | Phase 3 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 3 |
| Cytarabine | None of these genes | Phase 3 |
| Dactinomycin | None of these genes | Phase 3 |
| Daunorubicin | None of these genes | Phase 3 |
| Doxorubicin | None of these genes | Phase 3 |
| Etoposide | None of these genes | Phase 3 |
| Filgrastim | None of these genes | Phase 3 |
| Fludarabine | None of these genes | Phase 3 |
| Flumatinib | ABL1 | Phase 3 |
| Idarubicin | None of these genes | Phase 3 |
| Interferon | None of these genes | Phase 3 |
| Interferon Alfa | None of these genes | Phase 3 |
| Interferon Alfa-2a | None of these genes | Phase 3 |
| Melphalan | None of these genes | Phase 3 |
| Mercaptopurine Anhydrous | None of these genes | Phase 3 |
| Methotrexate | None of these genes | Phase 3 |
| Methylprednisolone | None of these genes | Phase 3 |
| Mitoxantrone | None of these genes | Phase 3 |
| Olverembatinib | ABL1, BCR | Phase 3 |
| Omacetaxine Mepesuccinate | None of these genes | Phase 3 |
| Omidubicel | None of these genes | Phase 3 |
| Pegaspargase | None of these genes | Phase 3 |
| Peginterferon Alfa-2a | None of these genes | Phase 3 |
| Prednisone | None of these genes | Phase 3 |
| Radotinib | ABL1, BCR | Phase 3 |
| Sargramostim | None of these genes | Phase 3 |
| Sirolimus | None of these genes | Phase 3 |
| Tacrolimus Anhydrous | None of these genes | Phase 3 |
| Tyrosine | None of these genes | Phase 3 |
| Vincristine | None of these genes | Phase 3 |
| Gemtuzumab Ozogamicin | None of these genes | Phase 2/3 |
| 2-Mercaptoethanesulfonic Acid | None of these genes | Phase 2 |
| Aldesleukin | None of these genes | Phase 2 |
| Alemtuzumab | None of these genes | Phase 2 |
| Alovudine | None of these genes | Phase 2 |
| Amifostine | None of these genes | Phase 2 |
| Arsenic Trioxide | None of these genes | Phase 2 |
| Asparaginase | None of these genes | Phase 2 |
| Aspirin | None of these genes | Phase 2 |
| Azacitidine | None of these genes | Phase 2 |
| Bevacizumab | None of these genes | Phase 2 |
| Bms-833923 | None of these genes | Phase 2 |
| Bortezomib | None of these genes | Phase 2 |
| Carboplatin | None of these genes | Phase 2 |
| Carmustine | None of these genes | Phase 2 |
| Cedazuridine | None of these genes | Phase 2 |
| Cladribine | None of these genes | Phase 2 |
| Clofarabine | None of these genes | Phase 2 |
| Cyclosporine | None of these genes | Phase 2 |
| Danusertib | None of these genes | Phase 2 |
| Decitabine | None of these genes | Phase 2 |
| Dexamethasone | None of these genes | Phase 2 |
| Dexrazoxane | None of these genes | Phase 2 |
| Fludarabine Phosphate | None of these genes | Phase 2 |
| Gemcitabine | None of these genes | Phase 2 |
| Gilteritinib | None of these genes | Phase 2 |
| Hydroxychloroquine | None of these genes | Phase 2 |
| Incomplete Freund'S Adjuvant | None of these genes | Phase 2 |
| Inecalcitol | None of these genes | Phase 2 |
| Ketoconazole | None of these genes | Phase 2 |
| Lenograstim | None of these genes | Phase 2 |
| Leucovorin | None of these genes | Phase 2 |
| Leuprolide | None of these genes | Phase 2 |
| Lintuzumab | None of these genes | Phase 2 |
| Lonafarnib | None of these genes | Phase 2 |
| Midostaurin | None of these genes | Phase 2 |
| Molgramostim | None of these genes | Phase 2 |
| Mycophenolate Mofetil | None of these genes | Phase 2 |
| Novaferon | None of these genes | Phase 2 |
| Oblimersen Sodium | None of these genes | Phase 2 |
| Panobinostat | None of these genes | Phase 2 |
| Pegfilgrastim | None of these genes | Phase 2 |
| Peginterferon Alfa-2b | None of these genes | Phase 2 |
| Pembrolizumab | None of these genes | Phase 2 |
| Pioglitazone | None of these genes | Phase 2 |
| Regramostim | None of these genes | Phase 2 |
| Ridaforolimus | None of these genes | Phase 2 |
| Rituximab | None of these genes | Phase 2 |
| Ropeginterferon Alfa-2b | None of these genes | Phase 2 |
| Ruxolitinib | None of these genes | Phase 2 |
| Sorafenib | None of these genes | Phase 2 |
| Temsirolimus | None of these genes | Phase 2 |
| Thalidomide | None of these genes | Phase 2 |
| Thiotepa | None of these genes | Phase 2 |
| Topotecan | None of these genes | Phase 2 |
| Tozasertib | None of these genes | Phase 2 |
| Triapine | None of these genes | Phase 2 |
| Troxacitabine | None of these genes | Phase 2 |
| Valproic Acid | None of these genes | Phase 2 |
| Venetoclax | None of these genes | Phase 2 |
| At-9283 | ABL1 | Phase 1/2 |
| Atezolizumab | None of these genes | Phase 1/2 |
| Avelumab | None of these genes | Phase 1/2 |
| Bendamustine | None of these genes | Phase 1/2 |
| Daclizumab | None of these genes | Phase 1/2 |
| Everolimus | None of these genes | Phase 1/2 |
| Icosapent | None of these genes | Phase 1/2 |
| Inotuzumab Ozogamicin | None of these genes | Phase 1/2 |
| Interferon Gamma-1b | None of these genes | Phase 1/2 |
| Interleukin-7 | None of these genes | Phase 1/2 |
| Melk Inhibitor | None of these genes | Phase 1/2 |
| Motixafortide | None of these genes | Phase 1/2 |
| Muromonab-Cd3 | None of these genes | Phase 1/2 |
| Navtemadlin | None of these genes | Phase 1/2 |
| Neratinib | None of these genes | Phase 1/2 |
| Paclitaxel | None of these genes | Phase 1/2 |
| Palifermin | None of these genes | Phase 1/2 |
| Plerixafor | None of these genes | Phase 1/2 |
| Pr1 Leukemia Peptide Vaccine | None of these genes | Phase 1/2 |
| Prexigebersen | None of these genes | Phase 1/2 |
| Pri-724 | None of these genes | Phase 1/2 |
| Tipifarnib | None of these genes | Phase 1/2 |
| Troculeucel | None of these genes | Phase 1/2 |
| Tucatinib | None of these genes | Phase 1/2 |
| Vamotinib | None of these genes | Phase 1/2 |
| Vatalanib | None of these genes | Phase 1/2 |
| Vodobatinib | ABL1, BCR | Phase 1/2 |
| Acetaminophen | None of these genes | Phase 1 |
| Adavosertib | None of these genes | Phase 1 |
| Alvocidib | None of these genes | Phase 1 |
| Apg-2575 | None of these genes | Phase 1 |
| Axitinib | None of these genes | Phase 1 |
| Belinostat | None of these genes | Phase 1 |
| Binimetinib | None of these genes | Phase 1 |
| Blinatumomab | None of these genes | Phase 1 |
| Bms-214662 | None of these genes | Phase 1 |
| Bryostatin 1 | None of these genes | Phase 1 |
| Cordycepin | None of these genes | Phase 1 |
| Dolastatin-10 | None of these genes | Phase 1 |
| Evofosfamide | None of these genes | Phase 1 |
| Exatecan | None of these genes | Phase 1 |
| Ganetespib | None of these genes | Phase 1 |
| Gti-2040 | None of these genes | Phase 1 |
| Idelalisib | None of these genes | Phase 1 |
| Ipilimumab | None of these genes | Phase 1 |
| Irinotecan | None of these genes | Phase 1 |
| Irofulven | None of these genes | Phase 1 |
| Ispinesib | None of these genes | Phase 1 |
| Kw-2449 | ABL1 | Phase 1 |
| Nivolumab | None of these genes | Phase 1 |
| Obatoclax | None of these genes | Phase 1 |
| Pentostatin | None of these genes | Phase 1 |
| Perifosine | None of these genes | Phase 1 |
| Rebastinib | ABL1 | Phase 1 |
| Rebeccamycin | None of these genes | Phase 1 |
| Rigosertib | None of these genes | Phase 1 |
| Ro-5045337 | None of these genes | Phase 1 |
| Sjg-136 | None of these genes | Phase 1 |
| Sonidegib | None of these genes | Phase 1 |
| Tanespimycin | None of these genes | Phase 1 |
| Ucn-01 | None of these genes | Phase 1 |
| Vorinostat | None of these genes | Phase 1 |
| Xl-228 | ABL1 | Phase 1 |
| Zileuton | None of these genes | Phase 1 |
| Fluconazole | None of these genes | Unknown |
| Voriconazole | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.